Plasma biomarkers for personalized medicine in cardiovascular diseases
| Reference number | |
| Coordinator | Kungliga tekniska högskolan - Skolan för bioteknologi |
| Funding from Vinnova | SEK 9 983 000 |
| Project duration | November 2011 - December 2013 |
| Status | Completed |
| Venture | Challenge-driven innovation - Phase 2 Collaboration |
Purpose and goal
The aim has been to identify new biomarkers of clinical and commercial relevance for cardiovascular disease. Furthermore, to build a legally binding constellation to form a unique model of sector spanning collaboration between health care providers (Karolinska University Hospital), clinical and preclinical researchers and technology developers (Karolinska Institutet, BBRMI.se, KTH/SciLifeLab) and industrial partners (Atlas Antibodies AB)
Results and expected effects
We have developed and implemented the interaction model, which will serve as a template for sector spanning collaborations in other disease areas. We have successfully demonstrated the combination of undirected discovery screenings and subsequent targeted screenings in expanded biobank materials, using affinity proteomics. Candidates for early acute coronary syndrome have been identified, which would be of high clinical and commercial potential if clinically validated
Approach and implementation
In VinnCardio we performed a unique affinity proteomics-based screen of biobanks representing 4 cardiovascular disease entities, covering >10,000 specific targets. Following three subsequent targeted proteomics screens, 9,835 proteins have been probed in 4 cohorts, with a total of 2,698 individual patient samples analysed. A number of highly interesting potential candidates for early diagnostics of acute coronary syndrome have now been identified.